Development
Moderna, Inc.
MRNA
$25.35
-$1.77-6.53%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 105.98% | -163.04% | -1,846.84% | -94.61% | 40.46% |
| Total Depreciation and Amortization | -18.88% | 170.65% | 17.95% | -2.50% | -29.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -102.88% | 895.52% | 15.55% | -561.11% | -- |
| Change in Net Operating Assets | 36.81% | -68.29% | 150.17% | -847.71% | 116.92% |
| Cash from Operations | 138.88% | -74.86% | 25.31% | -173.71% | 559.52% |
| Capital Expenditure | -57.14% | 40.17% | -107.08% | -22.83% | -3.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -134.23% | -57.35% | -1.40% | 331.07% | -192.46% |
| Cash from Investing | -168.19% | -59.41% | -3.33% | 291.89% | -210.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -90.77% | -16.07% | -124.00% | 59.02% | -32.61% |
| Issuance of Common Stock | 114.29% | -56.25% | 77.78% | -64.00% | 127.27% |
| Repurchase of Common Stock | -- | -- | -19.39% | -30.85% | 60.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -87.93% | 91.32% | -23.25% | -23.74% | 57.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.12% | -340.72% | 47.95% | 38.64% | 12.82% |